Announcement: A study showing CDNF's therapeutic effects in alpha-synuclein-based animal models published
Herantis Pharma Plc, Company release, 20 May 2021 at 11:45 AM EEST Herantis Pharma Plc (“Herantis or the Company”), focusing on disease modifying therapies for debilitating neurodegenerative diseases, announced today that a research paper that outlines the interaction of CDNF with α-synuclein and novel insights into the potential of CDNF as a therapeutic strategy in Parkinson’s disease and other synucleinopathies, was published online in the journal Molecular Therapy. ”Alpha-synuclein is the neuropathological hallmark and a major driver of disease progression in Parkinson’s disease.